Treatment Response in Myositis-Associated RP-ILD in Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study focusing on adults with immune-mediated myositis and rapidly progressive interstitial lung disease. It aims to describe treatment responses to immunosuppressant regimens used in real-world care, including factors that may influence outcomes. The investigation builds on existing knowledge that RP-ILD in anti-MDA5+ dermatomyositis carries high mortality and explores patterns of care and prognosis without random assignment. Data come from patients treated at Singapore General Hospital and related clinical centers. The study acknowledges the lack of randomized trials in this rare condition and seeks to inform future research and clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age of 21 years or above;
2. Diagnosis of myositis associated rapidly progressive interstitial lung disease

Exclusion Criteria:

1. Age of less than 21 year old;

Where it's running

• Singapore General Hospital
  Singapore, Singapore Recruiting

Study contacts

• Study coordinator: Mohamad Fadhli Bin Masri, MD PhD
• Email: mohamad.fadhli@mohh.com.sg
• Phone: 6576 2609

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• Imaging markers for bulbar involvement in inclusion body myositis among IBM and comparison groups

  This study tests whether ultrasound and MRI can detect swallowing and bulbar muscle problems in people with inclusion body myositis.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07823101

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.